A PTEN-Dependent Size Checkpoint in Human Cancer Cells
人类癌细胞中 PTEN 依赖性大小检查点
基本信息
- 批准号:7685028
- 负责人:
- 金额:$ 6.06万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2006
- 资助国家:美国
- 起止时间:2006-05-11 至 2011-03-31
- 项目状态:已结题
- 来源:
- 关键词:AffectAttenuatedBindingBiochemicalBiological ModelsCancer cell lineCell LineCell SizeCellsCharacteristicsDNA DamageDataDrosophila melanogasterG2 Checkpoint controlGTP-Binding ProteinsGene TargetingGenesGoalsGuanosine Triphosphate PhosphohydrolasesHCT116 CellsHouse miceHumanKnock-outKnowledgeLeadMalignant NeoplasmsMeasuresMutationNormal CellNumbersOncogenesOncogenicOrganismOxidative StressPIK3CA genePTEN genePathway interactionsPhenotypePhosphorylationPhosphotransferasesPoisonPropertyRadiationRadiation, OtherRangeReportingResearch PersonnelSignal TransductionSignal Transduction PathwaySmall Interfering RNASomatic CellStimulusSystemTP53 Gene InactivationTP53 geneTSC2 geneTestingTransfectionTumor Suppressor GenesTumor Suppressor ProteinsVariantWorkcancer cellhuman PIK3CA proteinnovelprogramsresponsesizesmall hairpin RNA
项目摘要
DESCRIPTION (provided by applicant): Activation of PIP3 signaling by inactivating mutations in the PTEN tumor suppressor or activating mutations in the PIK3CA oncogene is found in a wide range of common human cancers. Though the biochemical details of PIP3 signal transduction are rapidly emerging, the phenotypic consequences of PIP3 pathway activation in human cancer cells remain less well defined. As such, the long-term goal of this project is to define the effects of PIP3 activation in human cancer cells. In our initial preliminary studies, we employed human somatic cell gene targeting to create isogenic sets of PTEN+/+ and PTEN-/- human cancer cell lines. Using these and related model systems, we found that PTEN controls a novel radiation-induced size checkpoint in human cells that is distinct and genetically separable from the radiation-induced, p53-dependent G1 and G2 checkpoints. To our knowledge, the existence of such a DNA damage-inducible size arrest has neither been postulated or demonstrated in any organism. Since the initial submission of this application we have employed human somatic cell gene targeting to create an isogenic set of PIK3CA gene targeted human cancer cells, and also created NIH3T3 cell lines that express wild-type, oncogenic, or inactive forms of PIK3CA. Using these systems we have obtained preliminary data suggesting that, like PTEN, the PIK3CA oncogene may be able to regulate size checkpoint function as well. In this application we propose three related specific aims to further pursue and extend these observations. Aim #1 - Identify additional inducers of the PTEN-dependent size checkpoint. Aim #2 - Demonstrate the presence of the PTEN-dependent size checkpoint in untransformed human cells. Aim #3 - Characterize crosstalk between the radiation-induced, p53-dependent G1/G2 checkpoints and the radiation-induced, PTEN-dependent cell size checkpoint. Pursuit of these aims will enable us to further characterize the properties and mechanism(s) of a tumor suppressor gene-regulated, radiation-induced cell size checkpoint.
描述(由申请人提供):在广泛的常见人类癌症中发现通过失活PTEN肿瘤抑制基因中的突变或激活PIK 3CA癌基因中的突变来激活PIP 3信号传导。虽然PIP 3信号转导的生物化学细节正在迅速出现,但人类癌细胞中PIP 3途径活化的表型结果仍然不太清楚。因此,该项目的长期目标是确定PIP 3激活在人类癌细胞中的作用。在我们最初的初步研究中,我们采用人体细胞基因靶向来创建PTEN+/+和PTEN-/-人癌细胞系的等基因组。使用这些和相关的模型系统,我们发现,PTEN控制一种新的辐射诱导的大小检查点在人类细胞中,这是不同的和遗传上可分离的辐射诱导的,p53依赖的G1和G2检查点。据我们所知,这种DNA损伤诱导的大小停滞的存在既没有在任何生物体中被假设或证明。自首次提交本申请以来,我们已采用人体细胞基因靶向来创建PIK 3CA基因靶向的人癌细胞的等基因组,并且还创建了表达野生型、致癌或失活形式的PIK 3CA的NIH 3 T3细胞系。使用这些系统,我们已经获得了初步的数据,表明PIK 3CA癌基因,如PTEN,可能能够调节大小检查点功能以及。在本申请中,我们提出了三个相关的具体目标,以进一步追求和扩展这些观察。目的#1 -鉴定PTEN依赖性大小检查点的其他诱导物。目的#2 -证明在未转化的人细胞中存在PTEN依赖性大小检查点。目的#3 -表征辐射诱导的p53依赖性G1/G2检查点和辐射诱导的PTEN依赖性细胞大小检查点之间的串扰。追求这些目标将使我们能够进一步表征肿瘤抑制基因调控的辐射诱导的细胞大小检查点的特性和机制。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
TODD A WALDMAN其他文献
TODD A WALDMAN的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('TODD A WALDMAN', 18)}}的其他基金
Analysis of STAG2 Inactivation and Aneuploidy in Human Cancer
人类癌症中 STAG2 失活和非整倍性分析
- 批准号:
8501829 - 财政年份:2013
- 资助金额:
$ 6.06万 - 项目类别:
Analysis of STAG2 Inactivation and Aneuploidy in Human Cancer
人类癌症中 STAG2 失活和非整倍性分析
- 批准号:
8819107 - 财政年份:2013
- 资助金额:
$ 6.06万 - 项目类别:
Analysis of STAG2 Inactivation and Aneuploidy in Human Cancer
人类癌症中 STAG2 失活和非整倍性分析
- 批准号:
8633441 - 财政年份:2013
- 资助金额:
$ 6.06万 - 项目类别:
Analysis of STAG2 Inactivation and Aneuploidy in Human Cancer
人类癌症中 STAG2 失活和非整倍性分析
- 批准号:
9008028 - 财政年份:2013
- 资助金额:
$ 6.06万 - 项目类别:
Development and Application of Endogenous Epitope Tagging Technology in Human Cel
人细胞内源表位标记技术的开发及应用
- 批准号:
7777680 - 财政年份:2010
- 资助金额:
$ 6.06万 - 项目类别:
Development and Application of Endogenous Epitope Tagging Technology in Human Cel
人细胞内源表位标记技术的开发及应用
- 批准号:
8044714 - 财政年份:2010
- 资助金额:
$ 6.06万 - 项目类别:
A PTEN-Dependent Size Checkpoint in Human Cancer Cells
人类癌细胞中 PTEN 依赖性大小检查点
- 批准号:
7417921 - 财政年份:2006
- 资助金额:
$ 6.06万 - 项目类别:
A PTEN-Dependent Size Checkpoint in Human Cancer Cells
人类癌细胞中 PTEN 依赖性大小检查点
- 批准号:
7105903 - 财政年份:2006
- 资助金额:
$ 6.06万 - 项目类别:
A PTEN-dependent cell size checkpoint in human cells
人类细胞中 PTEN 依赖性细胞大小检查点
- 批准号:
8690786 - 财政年份:2006
- 资助金额:
$ 6.06万 - 项目类别:
A PTEN-dependent cell size checkpoint in human cells
人类细胞中 PTEN 依赖性细胞大小检查点
- 批准号:
8578465 - 财政年份:2006
- 资助金额:
$ 6.06万 - 项目类别:
相似海外基金
A platform for rapidly generating live attenuated enterovirus vaccines
快速生成减毒肠道病毒活疫苗的平台
- 批准号:
24K02286 - 财政年份:2024
- 资助金额:
$ 6.06万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
I-Corps: Translation potential of an efficient method to generate live-attenuated and replication-defective DNA viruses for vaccine development
I-Corps:一种有效方法的转化潜力,可生成用于疫苗开发的减毒活病毒和复制缺陷型 DNA 病毒
- 批准号:
2420924 - 财政年份:2024
- 资助金额:
$ 6.06万 - 项目类别:
Standard Grant
Developing a robust native extracellular matrix to improve islet function with attenuated immunogenicity for transplantation
开发强大的天然细胞外基质,以改善胰岛功能,并减弱移植的免疫原性
- 批准号:
10596047 - 财政年份:2023
- 资助金额:
$ 6.06万 - 项目类别:
Live attenuated non-transmissible (LANT) Klebsiella pneumoniae vaccines
肺炎克雷伯氏菌减毒非传染性 (LANT) 活疫苗
- 批准号:
10742028 - 财政年份:2023
- 资助金额:
$ 6.06万 - 项目类别:
Protecting Pigs From Enzootic Pneumonia: Rational Design Of Safe Attenuated Vaccines.
保护猪免受地方性肺炎:安全减毒疫苗的合理设计。
- 批准号:
BB/X017540/1 - 财政年份:2023
- 资助金额:
$ 6.06万 - 项目类别:
Research Grant
A “Goldilocks” live attenuated poultry vaccine for Infectious Coryza
用于传染性鼻炎的“Goldilocks”家禽减毒活疫苗
- 批准号:
LP210301365 - 财政年份:2023
- 资助金额:
$ 6.06万 - 项目类别:
Linkage Projects
A novel live-attenuated Zika vaccine with a modified 5'UTR
一种带有改良 5UTR 的新型寨卡减毒活疫苗
- 批准号:
10730832 - 财政年份:2023
- 资助金额:
$ 6.06万 - 项目类别:
Combating melanoma with an attenuated bacterial therapeutic
用减毒细菌疗法对抗黑色素瘤
- 批准号:
10659841 - 财政年份:2023
- 资助金额:
$ 6.06万 - 项目类别:
Investigating Host and Viral Factors for Improved Design of Future Live Attenuated Vaccines for IBV
研究宿主和病毒因素以改进未来 IBV 减毒活疫苗的设计
- 批准号:
BB/V016067/1 - 财政年份:2022
- 资助金额:
$ 6.06万 - 项目类别:
Research Grant
L2M NSERC-Bioengineering attenuated Sclerotinia sclerotiorum strains as bioherbicide for cereal production and lawn management
L2M NSERC-生物工程减毒核盘菌菌株作为谷物生产和草坪管理的生物除草剂
- 批准号:
576545-2022 - 财政年份:2022
- 资助金额:
$ 6.06万 - 项目类别:
Idea to Innovation














{{item.name}}会员




